Semaglutide Research Peptide (GLP-1 Receptor Agonist) Supplier — UPOR Biotech
Semaglutide — a 31-amino-acid GLP-1 receptor agonist with a ~165-hour once-weekly half-life achieved through Aib⁸ DPP-IV resistance and Lys²⁶ C18 fatty diacid albumin binding. Activates the GLP-1R incretin pathway to drive glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. UPOR Biotech is a bulk research peptide supplier of ≥98% HPLC semaglutide lyophilized powder for metabolic, obesity, and diabetes research.
Request a QuoteProduct Overview
Semaglutide (CAS 910463-68-2, C₁₈₇H₂₉₁N₄₅O₅₉, MW 4113.58 g/mol) is a 31-amino-acid synthetic analogue of human GLP-1(7-37) with 94% sequence homology to the native incretin hormone. Three structural modifications convert the short-lived endogenous peptide into a once-weekly GLP-1 receptor agonist with a ~165-hour half-life: (1) Aib⁸ — substitution of α-aminoisobutyric acid for alanine at position 8 confers resistance to DPP-IV protease cleavage; (2) Lys²⁶ C18 fatty diacid acylation — octadecanedioic acid attached via a γ-Glu spacer and two AEEA linkers enables reversible albumin binding that slows renal clearance; and (3) reduced aggregation. As a GLP-1R agonist, semaglutide triggers glucose-dependent insulin secretion (active only when glucose is elevated, minimizing hypoglycemia risk), suppresses glucagon release, delays gastric emptying, and reduces appetite through central satiety signaling. UPOR Biotech supplies semaglutide as a white to off-white lyophilized powder with ≥98% HPLC purity for reproducible research outcomes.
As a leading GLP-1 receptor agonist reference peptide supplier, UPOR Biotech provides research-grade semaglutide for metabolic, obesity, and type 2 diabetes research programs worldwide. Semaglutide is the active principle of the FDA-approved agents Ozempic, Wegovy, and Rybelsus (reference only — this product is not a pharmaceutical), making it the industry-standard reference peptide for incretin biology and GLP-1R pharmacology studies. From a research and commercial standpoint, semaglutide is the preferred once-weekly incretin mimetic for preclinical efficacy, formulation, and drug-delivery studies due to its extended half-life and well-characterized pharmacology. This material is supplied exclusively for Research Use Only (RUO) — not for human diagnostic or therapeutic use. Every lot is manufactured under ISO 9001 and cGMP conditions with FDA facility registration, and is packaged in 1 mg, 5 mg, 10 mg, and 50 mg vials with full analytical documentation.
Semaglutide vs Liraglutide / Exenatide — Once-Weekly C18 Diacid Acylation & DPP-IV-Resistant Aib⁸ Modification
When comparing semaglutide vs liraglutide or exenatide, the defining difference is the fatty acid chain length and linker design that determine half-life. Liraglutide is acylated with a C16 palmitic acid at Lys²⁶ via a single γ-Glu spacer, yielding a ~13-hour plasma half-life and once-daily dosing. Exenatide is a short-acting GLP-1R agonist requiring twice-daily administration. Semaglutide instead uses a C18 octadecanedioic acid attached through a γ-Glu spacer plus two AEEA (8-amino-3,6-dioxaoctanoic acid) linkers — this longer diacid and extended linker dramatically strengthen reversible albumin binding, reducing renal clearance and extending the half-life to ~165 hours, enabling once-weekly administration. Semaglutide additionally incorporates the DPP-IV-resistant Aib⁸ substitution, which liraglutide and exenatide lack. For researchers, semaglutide represents the benchmark once-weekly incretin mimetic for studies requiring sustained GLP-1R engagement.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Semaglutide Research Peptide (GLP-1 Receptor Agonist) |
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 g/mol |
| Amino Acid Residues | 31 (GLP-1(7-37) analogue) |
| Sequence Homology | 94% to human GLP-1(7-37) |
| Peptide Class | Synthetic GLP-1 receptor agonist / incretin mimetic |
| Key Modifications | Aib⁸ substitution; Lys²⁶ C18 diacid via γ-Glu + AEEA linker |
| Mechanism of Action | GLP-1 receptor (GLP-1R) agonist |
| Half-Life | ~165 hours (~1 week), enabling once-weekly administration |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥90% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water and DMSO; slightly soluble in PBS |
| Endotoxin | ≤1.0 EU/mg |
| Water Content (Karl Fischer) | ≤5.0% |
| Counter-ion | Acetate |
| pH | 4.0 – 6.0 (1 mg/mL in water) |
| Heavy Metals | ≤10 ppm |
| Storage | -20°C ± 5°C, protected from light, avoid repeated freeze-thaw cycles |
| Grade | Research Grade (RUO) |
| Applications | Metabolic, obesity, and type 2 diabetes research |
| Certifications | ISO 9001, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg vials (lyophilized) |
| Reconstitution | Sterile water or PBS; aliquot and avoid freeze-thaw |
| Shelf Life | 2 years at -20°C |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Semaglutide
Once-Weekly GLP-1R Activation via C18 Diacid Albumin Binding
Semaglutide’s Lys²⁶ is acylated with a C18 octadecanedioic acid through a γ-Glu spacer and two AEEA linkers. This reversible albumin binding shields the peptide from renal clearance and proteolysis, extending the half-life to ~165 hours for once-weekly dosing in research protocols.
~165-h Half-LifeDPP-IV-Resistant Aib⁸ Modification
Substitution of α-aminoisobutyric acid (Aib) for alanine at position 8 blocks DPP-IV cleavage at the Ala⁸–Glu⁹ bond. This modification prevents rapid enzymatic degradation, contributing to semaglutide’s prolonged in vivo activity.
DPP-IV Resistant≥98% HPLC Purity Lyophilized Research Peptide
Supplied as a white to off-white lyophilized powder with ≥98.0% HPLC purity, ≥90% peptide content, and ≤1.0 EU/mg endotoxin. Each lot includes full analytical documentation for reproducible, publication-ready results.
≥98% HPLC94% Sequence Homology to Native GLP-1(7-37)
Semaglutide retains 94% sequence homology to human GLP-1(7-37), preserving the native incretin pharmacology while the three targeted modifications confer once-weekly stability. The benchmark reference peptide for GLP-1R signaling studies.
94% HomologyApplications
Type 2 Diabetes & Metabolic Research
GLP-1R agonism drives glucose-dependent insulin secretion and glucagon suppression. Semaglutide is the reference peptide for preclinical models of type 2 diabetes, insulin sensitivity, and incretin-mediated glycemic control.
Obesity & Weight-Management Research
Semaglutide reduces food intake through central appetite suppression and satiety signaling, plus delayed gastric emptying. Ideal for energy homeostasis, adiposity, and weight-loss pharmacology studies.
GLP-1 Receptor Signaling/GPCR Studies
Probe GLP-1R pharmacology including cAMP accumulation, β-arrestin recruitment, receptor internalization, and downstream kinase signaling in cell-based and ex vivo assays.
Combination Peptide (CagriSema-style) Research
Evaluate semaglutide in combination with amylin analogues (cagrilintide) and other incretin or appetite-regulating peptides for synergistic metabolic efficacy in dual-agonist research programs.
Formulation & Drug-Delivery Studies
Study albumin-binding half-life extension, oral and liposomal delivery, sustained-release formulations, and stability optimization for once-weekly peptide therapeutics.
Incretin Mimetic Reference Standard
Use as a high-purity analytical reference for HPLC and mass spectrometry method development, bioassay calibration, and comparator benchmarking in incretin mimetic research.
Frequently Asked Questions
Semaglutide (CAS 910463-68-2) is a 31-amino-acid synthetic analogue of human GLP-1(7-37) with 94% sequence homology. It is a GLP-1 receptor (GLP-1R) agonist — binding to the incretin receptor activates glucose-dependent insulin secretion (insulin is released only when blood glucose is elevated, minimizing hypoglycemia risk), suppresses glucagon, delays gastric emptying, and reduces appetite through central satiety pathways. Three structural modifications — Aib⁸ (DPP-IV resistance), Lys²⁶ C18 fatty diacid acylation (albumin binding), and reduced aggregation — extend its half-life to ~165 hours, enabling once-weekly activity in research models.
Three modifications confer semaglutide’s ~165-hour once-weekly half-life. (1) Aib⁸ — α-aminoisobutyric acid replaces alanine at position 8, blocking DPP-IV proteolytic cleavage. (2) Lys²⁶ C18 fatty diacid acylation — octadecanedioic acid attached via a γ-Glu spacer and two AEEA linkers enables reversible, high-affinity albumin binding that shields the peptide from renal clearance and degradation. (3) Reduced aggregation improves stability and manufacturability. Together these convert the ~2-minute endogenous GLP-1 half-life into a once-weekly research peptide.
Store lyophilized semaglutide at -20°C ± 5°C, protected from light and moisture, for up to 2 years. Reconstitute in sterile water, PBS, or DMSO as required by your protocol — semaglutide is freely soluble in water and DMSO, and slightly soluble in PBS. Avoid repeated freeze-thaw cycles; aliquot reconstituted solutions and store at -20°C or -80°C, discarding unused portions after a single thaw to preserve peptide integrity. Always verify solubility and stability in your specific buffer before use.
Semaglutide and liraglutide are both GLP-1 receptor agonists differing primarily in fatty acid length: liraglutide is acylated with a C16 palmitic acid (once-daily, ~13-hour half-life), while semaglutide uses a C18 octadecanedioic acid with a longer γ-Glu/AEEA linker (once-weekly, ~165-hour half-life). Tirzepatide is a dual GIP/GLP-1 receptor co-agonist that activates both incretin receptors, whereas semaglutide is a selective GLP-1R agonist. For GLP-1R-specific pharmacology studies, semaglutide is the benchmark once-weekly reference peptide.
Every lot of semaglutide is shipped with complete documentation including: COA (≥98% HPLC purity, ≥90% peptide content, ≤1.0 EU/mg endotoxin, ≤5% water content, heavy metals ≤10 ppm), MSDS, HPLC chromatogram, mass spectrometry (MS) data confirming molecular weight 4113.58 g/mol, sequence verification, and endotoxin analysis. Manufacturing is performed under ISO 9001 and cGMP with FDA facility registration. A Research Use Only (RUO) statement accompanies each order, confirming the material is not for human diagnostic or therapeutic use.